- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02312089
GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles
October 27, 2023 updated by: Mohamed Sayed Abdelhafez, Mansoura University
Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Gonadotropin Releasing Hormone Antagonist Protocol Cycles
Evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist (GnRHa) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (ICSI) following GnRH antagonist protocol
Study Overview
Detailed Description
Endometrial preparation for embryo transfer (ET) will be started after oocyte retrieval by giving 800 mg/day natural progesterone vaginal supplement + 4 mg/day estradiol oral supplement.
The patients will be randomly divided into 2 groups for luteal phase support: (i) Group A (GnRHa group) in which the luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval, and (ii) Group B (control group) in which the luteal phase support will be continued only by the same regimen started on the day of oocytes retrieval until 2 weeks after ET
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mohamed S Abdelhafez, Dr
- Phone Number: +201144523366
- Email: msabdelhafez@gmail.com
Study Locations
-
-
Dakahlia
-
Mansourah, Dakahlia, Egypt
- Recruiting
- Private fertility care centers
-
Mansourah, Dakahlia, Egypt, 35111
- Recruiting
- Fertility Care Unit (FCU) in Mansoura University Hospital
-
Contact:
- Mohamed S Abdelhafez, Dr
- Phone Number: +201144523366
- Email: msabdelhafez@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 38 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRH antagonist.
Exclusion Criteria:
- Moderate or severe endometriosis.
- Hydrosalpinx.
- Uterine abnormalities.
- Myoma.
- Previous uterine surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: GnRHa group
Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
|
Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
Other Names:
|
No Intervention: Control group
No GnRHa administration in luteal phase
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical pregnancy rate
Time Frame: 6 weeks after embryo transfer
|
Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of ET procedures
|
6 weeks after embryo transfer
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implantation rate
Time Frame: 6 weeks after embryo transfer
|
Number of gestational sacs on TVS scan at 4-6 weeks after ET divided by the number of transferred embryos
|
6 weeks after embryo transfer
|
Miscarriage rate
Time Frame: 12 weeks gestational age
|
Number of first trimester miscarriages (before 12 weeks gestational age) divided by the number of clinical pregnancies
|
12 weeks gestational age
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Waleed El-refaie, Dr, Port Said University
- Principal Investigator: Mohamed S Abdelhafez, Dr, Mansoura University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 7, 2016
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
December 5, 2014
First Submitted That Met QC Criteria
December 8, 2014
First Posted (Estimated)
December 9, 2014
Study Record Updates
Last Update Posted (Actual)
October 30, 2023
Last Update Submitted That Met QC Criteria
October 27, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MSA4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey
Clinical Trials on Triptorelin
-
Nanjing UniversityUnknownPolycystic Ovary Syndrome | In Vitro FertilizationChina
-
Aristotle University Of ThessalonikiEugonia IVF Unit, Athens, GreeceUnknown
-
ChenshilingNational Natural Science Foundation of China; Comprehensive Strategic Cooperation... and other collaboratorsUnknown
-
IVI MadridCompletedOvarian Hyperstimulation SyndromeSpain
-
Masaryk UniversityMinistry of Health, Czech RepublicCompletedHodgkin Disease | Hodgkin LymphomaCzech Republic
-
Universitair Ziekenhuis BrusselUniversitaire Ziekenhuizen KU LeuvenRecruitingBreast Cancer FemaleBelgium
-
Kaunas University of MedicineUnknown
-
Tampere University HospitalCompleted
-
Parc de Salut MarCompletedHealthy VolunteersSpain